Focusing on the treatment of patients receiving regorafenib, the panel details the management of common adverse events, prophylaxis strategies, and the roles of members within a multidisciplinary team.
Commitments to AML Research Uncover Numerous Targets in Relapsed/Refractory Disease
FDA Approval Insights: Ponatinib in Ph+ ALL
EMA Validates MAA for Frontline Nivolumab/Ipilimumab for MSI-H/dMMR mCRC
CRC Experts Highlight AE Management and Prevention Strategies for TAS-102/Bevacizumab, Regorafenib, and Fruquintinib
Fruquintinib Receives Positive CHMP Opinion for Previously Treated mCRC
Next-Generation ColoAlert Screening Test Shows High Sensitivity, Specificity for CRC and Adenoma Detection
Time to Bladder Cancer Treatment Is Similar Among Black and White Patients, But Other Disparities Persist
Dr Jia on the Evolving Role of Metastasis-Directed Radiotherapy in Prostate Cancer
Dr Wang on the Limited Utility of Quantitative Molecular Imaging Thresholds in RCC
Darolutamide Use Is Routine in Both Doublets and Triplet Therapies in mHSPC